呂永楠 陳晶晶 蔣學(xué)俊
急性冠脈綜合征患者新喋呤、D-二聚體和超敏C反應(yīng)蛋白水平變化*
呂永楠 陳晶晶 蔣學(xué)俊#
目的觀察急性冠脈綜合征(ACS)患者新蝶呤(NP)、D-二聚體(DD)和超敏C反應(yīng)蛋白(hs-CRP)水平變化,探討其在ACS中的臨床應(yīng)用價(jià)值。方法2016-01-2016-07武漢大學(xué)人民醫(yī)院心內(nèi)科住院ACS患者120例(觀察組),包含不穩(wěn)定性心絞痛(UA組,n=55)和急性心肌梗死(AMI組,n=65);選擇同期健康人群120例為對(duì)照(對(duì)照組)。采集受試者空腹肘靜脈血,采用酶聯(lián)免疫吸附法測(cè)定血清NP,全自動(dòng)凝血分析儀測(cè)定血漿DD,全自動(dòng)生化分析儀測(cè)定血清hs-CRP水平,比較各組各指標(biāo)差異。結(jié)果觀察組NP、DD和hs-CRP濃度較對(duì)照組顯著升高,分別為NP(2.84±0.05ng/ml vs 1.26±0.07ng/ml),DD(0.51±0.04mg/L vs 0.22±0.06mg/L),hs-CRP(0.52±0.57mg/L vs 0.11±0.52mg/L),差異均有統(tǒng)計(jì)學(xué)意義(P<0.01);并且AMI組NP、DD和hs-CRP水平高于UA組患者,分別為NP(2.89±0.05ng/ml vs 2.76±0.05ng/ml),DD(0.55±0.04mg/L vs 0.43±0.06mg/L),hs-CRP(0.59±0.63mg/L vs 0.37±0.19mg/L),差異亦有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論ACS患者NP、DD和hs-CRP指標(biāo)檢測(cè)能夠有效評(píng)估患者病情,具有重要的臨床應(yīng)用價(jià)值。
急性冠脈綜合征;新蝶呤;D-二聚體;超敏C反應(yīng)蛋白
冠狀動(dòng)脈粥樣硬化性心臟病(以下簡(jiǎn)稱冠心病)是目前發(fā)病率較高的心血管疾病,確切的病因尚不明確,與多種危險(xiǎn)因素相關(guān)。目前認(rèn)為冠心病是一種慢性炎癥性疾病,炎性因子在動(dòng)脈粥樣硬化血小板聚集、血栓形成以及并發(fā)癥中發(fā)揮著關(guān)鍵作用[1-2]。其中,急性冠脈綜合征(Acute Coronary Syndrome,ACS)是冠心病中的危急重癥,易導(dǎo)致患者發(fā)生猝死、急性心力衰竭和惡性心律失常,是臨床重點(diǎn)評(píng)估的心血管疾病之一[3]。新蝶呤(Neopterin,NP)是單核/巨噬細(xì)胞在活化的T淋巴細(xì)胞分泌釋放γ-干擾素(IFN-γ)的刺激下產(chǎn)生的一種低分子喋啶類化合物,與不穩(wěn)定性斑塊密切相關(guān)[4]。超敏C反應(yīng)蛋白(High-sensitivity C-reactive Protein,hs-CRP)已被證實(shí)是冠心病患者發(fā)生心血管事件的獨(dú)立危險(xiǎn)因子。動(dòng)脈粥樣硬化是冠心病發(fā)生的病理基礎(chǔ),與纖溶-凝血系統(tǒng)失衡及血管內(nèi)皮細(xì)胞損傷相關(guān)[5]。纖溶系統(tǒng)激活形成血栓是導(dǎo)致急性心血管事件發(fā)生的基礎(chǔ),D-二聚體(D-dimer,DD)是纖溶酶作用于交聯(lián)纖維蛋白降解形成的一種特異性產(chǎn)物,研究證實(shí)DD在冠心病風(fēng)險(xiǎn)評(píng)估和早期診斷中具有重要價(jià)值[6]。因此,本研究通過對(duì)NP、DD和hs-CRP水平的檢測(cè),分析該指標(biāo)對(duì)ACS患者的臨床應(yīng)用價(jià)值。
2016-01-2016-07武漢大學(xué)人民醫(yī)院心內(nèi)科住院的120例ACS患者(觀察組),其診斷均符合冠心病相關(guān)診斷標(biāo)準(zhǔn)[7],其中男87例,女33例,年齡51-74歲,平均61.27±8.21歲。排除冠心病之外腦梗死、肺栓塞、靜脈血栓等血栓性疾病、感染性疾病、免疫性疾病、腫瘤、肝腎功能不全等。將觀察組按疾病種類再分為不穩(wěn)定性心絞痛(Unstable Angina,UA)組(n=55)和急性心肌梗死(Acute Myocardial Infarction,AMI)組(n=65)。選擇同期健康人群120例為對(duì)照組,其中男82例,女38例,年齡52-72歲,平均63.04±7.70歲。觀察組與對(duì)照組患者性別(χ2=2.79,P=0.44)、年齡(t=1.14,P=0.61)差異均無統(tǒng)計(jì)學(xué)意義。
對(duì)照組于禁食8h后、觀察組患者還未行相關(guān)治療前清晨采集肘靜脈血8ml分為兩管,分別分離血清和血漿后置于有蓋試管中于-70℃貯存,待樣本收集完整后集中檢測(cè)。檢測(cè)時(shí)從冰箱取出,室溫溶解后,檢測(cè)以下指標(biāo):(1)血清NP采用酶聯(lián)免疫吸附法檢測(cè)(試劑盒購(gòu)自上海Bogoo科技公司);(2)血清hs-CRP采用免疫比濁法檢測(cè)(使用日本Olympus AU5400全自動(dòng)生化分析儀及配套試劑);(3)血漿DD采用日本Sysmex CA7000全自動(dòng)凝血分析儀及原裝進(jìn)口配套的試劑進(jìn)行測(cè)定。
觀察組冠心病患者血清NP、hs-CRP水平以及血漿DD水平均較對(duì)照組升高,差異具有統(tǒng)計(jì)學(xué)意義(P<0.01),見表1。
表1 觀察組與對(duì)照組NP、DD和hs-CRP水平比較均=120)
注:與對(duì)照組比較,1)P<0.01
試驗(yàn)組各亞組分析中,AMI組患者血清NP、hs-CRP水平及血漿DD水平均較UA組明顯升高,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05),見表2。
表2 UA組和AMI組NP、DD和hs-CRP水平比較
注:與UA組比較,1)P<0.05
目前研究證實(shí),動(dòng)脈粥樣硬化是一種慢性炎癥性疾病,斑塊局部炎癥反應(yīng)加重,促使穩(wěn)定性斑塊發(fā)展為不穩(wěn)定性斑塊,進(jìn)而導(dǎo)致斑塊破裂,誘發(fā)血栓形成,促使ACS事件的發(fā)生,嚴(yán)重危及患者生命[8]。斑塊破裂和血栓形成是由斑塊自身形態(tài)特點(diǎn)、炎性細(xì)胞浸潤(rùn)、細(xì)胞因子和各種高危因素共同作用的結(jié)果。
NP是氧化應(yīng)激反應(yīng)高敏感分子[9],也是全身炎癥反應(yīng)的敏感生物標(biāo)志物,與多種慢性免疫激活有關(guān),是心血管風(fēng)險(xiǎn)評(píng)估的獨(dú)立預(yù)測(cè)因子[10]。現(xiàn)有研究已證實(shí)炎癥反應(yīng)伴隨ACS發(fā)生發(fā)展的始終,NP與斑塊的易損性有相當(dāng)強(qiáng)的關(guān)聯(lián)性。本文結(jié)果顯示,觀察組患者血清NP水平較對(duì)照組升高,并且AMI組NP水平較UA組患者明顯升高,而NP水平升高反映單核/巨噬細(xì)胞激活程度,提示ACS患者存在巨噬細(xì)胞數(shù)量增多和單核免疫系統(tǒng)激活,這是導(dǎo)致斑塊不穩(wěn)定從而促使急性心血管事件發(fā)生的重要原因。因此NP水平檢測(cè)對(duì)斑塊炎癥狀態(tài)和不穩(wěn)定性斑塊評(píng)估均具有重要作用,與有關(guān)研究[11]結(jié)果一致。
hs-CRP是評(píng)估心血管疾病的獨(dú)立危險(xiǎn)因子[12],本文結(jié)果顯示試驗(yàn)組患者h(yuǎn)s-CRP濃度較對(duì)照組明顯升高,并且AMI組hs-CRP水平明顯高于UA組,這是由于在動(dòng)脈粥樣硬化慢性炎癥反應(yīng)過程中,急性炎癥反應(yīng)加重導(dǎo)致斑塊不穩(wěn)定性增加,繼而破裂形成急性血栓,是導(dǎo)致ACS發(fā)生的主要機(jī)制[2]。
冠心病患者存在凝血和纖溶系統(tǒng)功能紊亂[13]。體內(nèi)血栓形成時(shí),易誘發(fā)纖溶系統(tǒng)激活,血栓溶解,繼而形成繼發(fā)性纖溶亢進(jìn)。DD是纖維蛋白單體經(jīng)活化因子XIII交聯(lián)后,再經(jīng)纖溶酶水解所產(chǎn)生的一種特異性降解產(chǎn)物,DD濃度增高表明體內(nèi)血栓形成和繼發(fā)性纖溶亢進(jìn),是活動(dòng)性血栓的分子標(biāo)志物。有研究發(fā)現(xiàn),高濃度的DD與冠心病嚴(yán)重程度密切相關(guān),可以作為心血管事件的獨(dú)立預(yù)測(cè)指標(biāo)[14]。本文結(jié)果顯示,觀察組DD較對(duì)照組明顯升高(P<0.05),提示觀察組形成血栓風(fēng)險(xiǎn)高于對(duì)照組。同時(shí),觀察組亞組分析顯示,AMI組DD濃度較UA組升高,說明DD濃度越高,UA患者發(fā)展成為AMI急性心血管事件風(fēng)險(xiǎn)越大。
總之,冠心病是多因素共同作用的結(jié)果,存在血管內(nèi)皮炎癥反應(yīng)、凝血和纖溶系統(tǒng)激活和功能紊亂,并伴隨動(dòng)脈粥樣硬化發(fā)展全過程。AMI是較UA病情更為嚴(yán)重、危險(xiǎn)程度更為兇險(xiǎn)的疾病,NP、DD和hs-CRP與ACS的發(fā)生發(fā)展密切相關(guān),是評(píng)估患者病情嚴(yán)重程度,進(jìn)行危險(xiǎn)分層的有效指標(biāo),對(duì)于ACS防治和評(píng)估預(yù)后具有重要的臨床應(yīng)用價(jià)值。
?
本文第一作者簡(jiǎn)介:
呂永楠(1983-),男,漢族,博士,主治醫(yī)師,研究方向?yàn)楣谛牟〉呐R床診治
1 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease[J]. N Engl J Med, 2005, 352(4):1 685-1 695.
2 Avanzas P, Arroyo-Espliguero R, Cosín-Sales, J, et al. Markers of inflammation and multiple complexstenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes[J]. Heart, 2004,90(8): 847-852.
3 Sanchis-Gomar F, Perez-Quilis C, Leischik R,et al. Epidemiology of coronaryheart disease and acute coronary syndrome[J]. Ann Transl Med,2016,4(13):256.
4 De Rosa S, Cirillo P, Pacileo M. Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology[J]. Curr Vasc Pharmacol,2011,9(2):188-199.
5 Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists' view[J]. Eur heart J, 2013, 34(10):719-728.
6 Loon JE, Maat MP, Deckers JW. Prognostic markers in young patients with premature cornary heart disease[J]. Atherosclerosis, 2012,224(1):213-217.
7 Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHAfocused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non·-ST-Elevation Myocardial Infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 201l,57:e215-367.
8 Rosenson RS,Stafforini DM.Modulation of oxidative stress, inflammation and atherosclerosis by lipoprotein-associated phospholipase A2[J]. J Lipid Res, 2012, 53(9):1 767-1 782.9 Murr C, Widner B, Wirleitner B, et al. Neopterin as a marker for immune system activation[J]. Curr Drug Metab, 2002, 3 (2):175-187.
10 Fuchs D, Avanzas P, Arroyo-Espliguero R, et al. The role of neopterin in atherogenesis and cardiovascular risk assessment[J]. Curr Med Chem, 2009,16 (35):4 644-4 653.
11 Adachi T, Naruko T, Itoh A, et al. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions[J]. Heart, 2007,93 (12):1 537-1 541.
12 Ribeiro DR, Ramos AM, Vieira PL, et al. High-sensitivity C-reactive protein as a predictor of cardiovascular events after ST-elevation myocardial infarction[J]. Arq Bras Cardiol, 2014, 103(1):69-75.
13 Rosenfeld ME. An overview of the evoluation of the atheroscle rotic plaque: from fatty streak to plaque rupture and ttu'ombsis[J]. Z Kardiol, 2000, 89(suppl7):2-6.
14 Chang SS, Lee SH, Wu JY, et al. Evaluation of value of rapid D-dimer test in conjunction with cardiac troponin I test for early risk stratification of myocardial infarction[J]. J Thromb Thromholysis, 2010,30(2):472-478.
LevelsofNeopterin,D-DimerandHigh-SensitivityC-ReactiveProteininSerumofPatientswithAcuteCoronarySyndrome
LYU Yong-nan, CHEN Jing-jing, JIANG Xue-jun#
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China;#Corresponding author
Objective: To investigate the value of clinical application in acute coronary syndrome(ACS) by measuring serum levels of neopterin (NP), D-Dimer(DD) and high-sensitivity C-reactive protein(hs-CRP).MethodWe enrolled 120 ACS patients admitted to the Department of Cardiology at Renmin Hospital, Wuhan University between January 2016 and July 2016 into the experimental group(UA group,n=55, AMI group,n=65). At the same time, this study enrolled 120 healthy people into the control group. The subjects were collected from venous venous blood. The enzyme-linked immunosorbent assays(ELISAs)were used to measure the sernm NP level. The DD was assessen using automatic coagulation analyzerand. The hs-CRP was assessed using fully automatic biochemical analyzers. We compared the differences in each group's indexes.ResultsThe levels of NP, DD and hs-CRP were higher in the experimental group than that in the control group. NP (2.84±0.05) vs (1.26±0.07) ng/ml, DD (0.51±0.04) vs (0.22±0.06)mg/L, hs-CRP (0.52±0.57) vs (0.11±0.52)mg/L. In addition, the level of NP, DD and hs-CRP in the AMI group were also higher than that in UA group (P<0.05).ConclusionThe levels of NP, DD and hs-CRP could preferably reflect the severe degree of ACS, and had very important clinical value.
Acute coronary syndrome; Neopterin; D-Dimer; High-sensitivity C-reactive protein
10.3969/j.issn.1005-1740.2017.04.009
R541.4 R446.11
A
1005-1740(2017)04-0043-04
湖北省自然科學(xué)基金(2017CFB172)
武漢大學(xué)人民醫(yī)院心內(nèi)科,武漢 430060;#
,E-mail:xjjiang@whu.edu.cn
本文2017-05-15收到,2017-09-18修回